S

South Texas Accelerated Research Therapeutics | START Mountain Region

Research site
(Unclaimed)
Location
2965 West 3500 South, West Valley City, Utah, United States of America

Site insights

Top conditions

Top treatments

SM08502
SL-172154
Abiraterone Acetate
Osimertinib
LP-284
AB801
LP-184
LY3537982
Pembrolizumab
FMC-376

Parent organization

This site is a part of South Texas Accelerated Research Therapeutics

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

27 of 31 total trials

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metasta...

Enrolling
Advanced Solid Tumor
Drug: IMP1734

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study, designed to evaluate safety and preliminary efficacy of IA...

Enrolling
HER2 Mutation-Related Tumors
Drug: Trastuzumab
Drug: IAM1363

A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 as m...

Enrolling
Non-Small Cell Lung Cancer Metastatic
Gastric Cancer
Drug: MCLA-129
Drug: Osimertinib
Status recently updated

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of PBI-410 in participants with previously treated, advanced solid tumors.

Not yet enrolling
Enrolling
Solid Tumor
Drug: PBI-410

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will...

Enrolling
Solid Tumor, Adult
Unresectable Solid Tumor
Drug: FMC-376

This study is an open-label, multi-center, dose-escalation, dose-finding and expansion study in adult subjects with advanced solid tumors for whom no...

Active, not recruiting
Solid Tumor, Adult
Drug: SM08502

This study is an open-label, multi-center, dose-escalation, dose expansion study in adult subjects with advanced solid tumors. The study will evaluat...

Active, not recruiting
Non-small Cell Lung Cancer
Castration-resistant Prostate Cancer
Drug: SM08502
Drug: Prednisone

The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a re...

Enrolling
Advanced Cancer
Drug: Docetaxel
Drug: Zimberelimab

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patie...

Enrolling
Solid Tumors
Drug: ADRX-0706

The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in part...

Enrolling
Advanced Solid Tumors
Drug: Capecitabine
Drug: Docetaxel

The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and bioequivalence (BE; Period 2 and 3) of various strengths a...

Active, not recruiting
Prostatic Neoplasms
Drug: Prednisone
Drug: Niraparib

The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic cast...

Enrolling
Inhibitory Checkpoint Molecule
Immunotherapy
Drug: docetaxel
Drug: Prednisone

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose...

Enrolling
Relapsed or Refractory Lymphomas
Advanced Solid Tumor
Drug: LP-284

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in parti...

Enrolling
Small-cell Lung Cancer
Melanoma
Biological: MGC026 Dose Escalation
Biological: MGC026 Dose for Expansion
Locations recently updated

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.

Enrolling
Breast Cancer
Pancreas Cancer
Drug: IDE-161

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Pancreatic Ductal Adenocarcinoma
Drug: SGN-CEACAM5C

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal...

Enrolling
Breast Cancer
Melanoma
Drug: Cemiplimab
Drug: SNS-101 (anti-VISTA)

Genes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRA...

Enrolling
Solid Tumor
Drug: ASP4396

The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if...

Enrolling
Breast Cancer
Drug: vepdegestrant
Drug: PF-07220060

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolera...

Enrolling
Solid Tumor
Advanced Ovarian Carcinoma
Drug: NKT3447

Trial sponsors

B
L
MacroGenics logo
P
Seagen logo
A
A
Arcus Biosciences logo
Astellas logo
Bristol-Myers Squibb (BMS) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems